Literature DB >> 22550248

New approaches to targeted therapy in lung cancer.

William Pao1.   

Abstract

This brief report summarizes Dr. Pao's talk at the 54th Annual Meeting of the Thomas L. Petty Aspen Lung Conference, in Aspen, Colorado, on June 11, 2011. In this talk, Dr. Pao discussed three main topics: (1) DETECT (DNA Evaluation of Tumors for Enhanced Cancer Treatment), (2) MyCancerGenome.org (web-based decision support), and (3) DIRECT (DNA-mutation Inventory to Refine and Enhance Cancer Treatment).

Entities:  

Mesh：

Substances：

Year:  2012        PMID： 22550248      PMCID： PMC3359104          DOI： 10.1513/pats.201112-054MS

Source DB:  PubMed          Journal:  Proc Am Thorac Soc        ISSN： 1546-3222


  15 in total

1.  Anaplastic lymphoma kinase inhibition in non-small-cell lung cancer.

Authors:  Eunice L Kwak; Yung-Jue Bang; D Ross Camidge; Alice T Shaw; Benjamin Solomon; Robert G Maki; Sai-Hong I Ou; Bruce J Dezube; Pasi A Jänne; Daniel B Costa; Marileila Varella-Garcia; Woo-Ho Kim; Thomas J Lynch; Panos Fidias; Hannah Stubbs; Jeffrey A Engelman; Lecia V Sequist; WeiWei Tan; Leena Gandhi; Mari Mino-Kenudson; Greg C Wei; S Martin Shreeve; Mark J Ratain; Jeffrey Settleman; James G Christensen; Daniel A Haber; Keith Wilner; Ravi Salgia; Geoffrey I Shapiro; Jeffrey W Clark; A John Iafrate
Journal:  N Engl J Med       Date:  2010-10-28       Impact factor: 91.245

Review 2.  Lessons from hereditary colorectal cancer.

Authors:  K W Kinzler; B Vogelstein
Journal:  Cell       Date:  1996-10-18       Impact factor: 41.582

3.  A platform for rapid detection of multiple oncogenic mutations with relevance to targeted therapy in non-small-cell lung cancer.

Authors:  Zengliu Su; Dora Dias-Santagata; Markeesa Duke; Katherine Hutchinson; Ya-Lun Lin; Darrell R Borger; Christine H Chung; Pierre P Massion; Cindy L Vnencak-Jones; A John Iafrate; William Pao
Journal:  J Mol Diagn       Date:  2010-12-23       Impact factor: 5.568

4.  Genetically informed lung cancer medicine.

Authors:  William Pao; A John Iafrate; Zengliu Su
Journal:  J Pathol       Date:  2010-10-25       Impact factor: 7.996

5.  Cancer statistics, 2011: the impact of eliminating socioeconomic and racial disparities on premature cancer deaths.

Authors:  Rebecca Siegel; Elizabeth Ward; Otis Brawley; Ahmedin Jemal
Journal:  CA Cancer J Clin       Date:  2011-06-17       Impact factor: 508.702

6.  Lung adenocarcinoma from East Asian never-smokers is a disease largely defined by targetable oncogenic mutant kinases.

Authors:  Yihua Sun; Yan Ren; Zhaoyuan Fang; Chenguang Li; Rong Fang; Bin Gao; Xiangkun Han; Weidong Tian; William Pao; Haiquan Chen; Hongbin Ji
Journal:  J Clin Oncol       Date:  2010-09-20       Impact factor: 44.544

7.  Paclitaxel-carboplatin alone or with bevacizumab for non-small-cell lung cancer.

Authors:  Alan Sandler; Robert Gray; Michael C Perry; Julie Brahmer; Joan H Schiller; Afshin Dowlati; Rogerio Lilenbaum; David H Johnson
Journal:  N Engl J Med       Date:  2006-12-14       Impact factor: 91.245

8.  Gefitinib or carboplatin-paclitaxel in pulmonary adenocarcinoma.

Authors:  Tony S Mok; Yi-Long Wu; Sumitra Thongprasert; Chih-Hsin Yang; Da-Tong Chu; Nagahiro Saijo; Patrapim Sunpaweravong; Baohui Han; Benjamin Margono; Yukito Ichinose; Yutaka Nishiwaki; Yuichiro Ohe; Jin-Ji Yang; Busyamas Chewaskulyong; Haiyi Jiang; Emma L Duffield; Claire L Watkins; Alison A Armour; Masahiro Fukuoka
Journal:  N Engl J Med       Date:  2009-08-19       Impact factor: 91.245

9.  Cancer. Addiction to oncogenes--the Achilles heal of cancer.

Authors:  I Bernard Weinstein
Journal:  Science       Date:  2002-07-05       Impact factor: 47.728

10.  Spectrum of oncogenic driver mutations in lung adenocarcinomas from East Asian never smokers.

Authors:  Chenguang Li; Rong Fang; Yihua Sun; Xiangkun Han; Fei Li; Bin Gao; A John Iafrate; Xin-Yuan Liu; William Pao; Haiquan Chen; Hongbin Ji
Journal:  PLoS One       Date:  2011-11-30       Impact factor: 3.240
View more
  13 in total

1.  Targeted therapy for squamous cell lung cancer.

Authors:  Rachel G Liao; Hideo Watanabe; Matthew Meyerson; Peter S Hammerman
Journal:  Lung Cancer Manag       Date:  2012-12

2.  Peruvoside is a novel Src inhibitor that suppresses NSCLC cell growth and motility by downregulating multiple Src-EGFR-related pathways.

Authors:  Yihua Lai; Hsiuhui Chang; Hueiwen Chen; Geechen Chang; Jeremy Jw Chen
Journal:  Am J Cancer Res       Date:  2022-06-15       Impact factor: 5.942

Review 3.  How and when to use genetic markers for nonsmall cell lung cancer.

Authors:  Donald R Lazarus; David E Ost
Journal:  Curr Opin Pulm Med       Date:  2013-07       Impact factor: 3.155

4.  Development and validation of a clinical cancer genomic profiling test based on massively parallel DNA sequencing.

Authors:  Garrett M Frampton; Alex Fichtenholtz; Geoff A Otto; Kai Wang; Sean R Downing; Jie He; Michael Schnall-Levin; Jared White; Eric M Sanford; Peter An; James Sun; Frank Juhn; Kristina Brennan; Kiel Iwanik; Ashley Maillet; Jamie Buell; Emily White; Mandy Zhao; Sohail Balasubramanian; Selmira Terzic; Tina Richards; Vera Banning; Lazaro Garcia; Kristen Mahoney; Zac Zwirko; Amy Donahue; Himisha Beltran; Juan Miguel Mosquera; Mark A Rubin; Snjezana Dogan; Cyrus V Hedvat; Michael F Berger; Lajos Pusztai; Matthias Lechner; Chris Boshoff; Mirna Jarosz; Christine Vietz; Alex Parker; Vincent A Miller; Jeffrey S Ross; John Curran; Maureen T Cronin; Philip J Stephens; Doron Lipson; Roman Yelensky
Journal:  Nat Biotechnol       Date:  2013-10-20       Impact factor: 54.908

5.  Downregulation of MTSS1 expression is an independent prognosticator in squamous cell carcinoma of the lung.

Authors:  G Kayser; A Csanadi; S Kakanou; A Prasse; A Kassem; E Stickeler; B Passlick; A Zur Hausen
Journal:  Br J Cancer       Date:  2015-01-27       Impact factor: 7.640

6.  Rhodomycin A, a novel Src-targeted compound, can suppress lung cancer cell progression via modulating Src-related pathways.

Authors:  Yi-Hua Lai; Min-Hsuan Chen; Sih-Yin Lin; Sheng-Yi Lin; Yung-Hao Wong; Sung-Liang Yu; Huei-Wen Chen; Chih-Hsin Yang; Gee-Chen Chang; Jeremy J W Chen
Journal:  Oncotarget       Date:  2015-09-22

Review 7.  Available resources and challenges for the clinical annotation of somatic variations.

Authors:  Catherine I Dumur
Journal:  Cancer Cytopathol       Date:  2014-08-08       Impact factor: 5.284

8.  Endostatin enhances antitumor effect of tumor antigen-pulsed dendritic cell therapy in mouse xenograft model of lung carcinoma.

Authors:  Jing Liang; Xiaolin Liu; Qi Xie; Guoling Chen; Xingyu Li; Yanrui Jia; Beibei Yin; Xun Qu; Yan Li
Journal:  Chin J Cancer Res       Date:  2016-08       Impact factor: 5.087

9.  AC-93253 iodide, a novel Src inhibitor, suppresses NSCLC progression by modulating multiple Src-related signaling pathways.

Authors:  Yi-Hua Lai; Sih-Yin Lin; Yu-Shan Wu; Huei-Wen Chen; Jeremy J W Chen
Journal:  J Hematol Oncol       Date:  2017-11-13       Impact factor: 17.388

10.  A targeted next-generation sequencing method for identifying clinically relevant mutation profiles in lung adenocarcinoma.

Authors:  Di Shao; Yongping Lin; Jilong Liu; Liang Wan; Zu Liu; Shaomin Cheng; Lingna Fei; Rongqing Deng; Jian Wang; Xi Chen; Liping Liu; Xia Gu; Wenhua Liang; Ping He; Jun Wang; Mingzhi Ye; Jianxing He
Journal:  Sci Rep       Date:  2016-03-03       Impact factor: 4.379
View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.